Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - Recro Pharma, Inc. | d216742d10q.htm |
| EX-31.3 - EX-31.3 - Recro Pharma, Inc. | d216742dex313.htm |
| EX-31.2 - EX-31.2 - Recro Pharma, Inc. | d216742dex312.htm |
| EX-31.1 - EX-31.1 - Recro Pharma, Inc. | d216742dex311.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Recro Pharma, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to such officer’s knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: August 11, 2016
| /s/ Gerri A. Henwood |
| Gerri A. Henwood |
| President and Chief Executive Officer |
| (Principal Executive Officer) |
| /s/ Michael Celano |
| Michael Celano |
| Chief Financial Officer |
| (Principal Financial Officer) |
| /s/ Donna M. Nichols |
| Donna M. Nichols |
| Corporate Controller and Chief Accounting Officer |
| (Principal Accounting Officer performing the functions of the Principal Financial Officer) |